[SP-4-2-(1R-trans)]-(1,2-Cyclohexanediamine-N,N’) Dichloridoplatinum(II)
CAS: 61848-66-6
Ref. TR-C987465
10mg | Descatalogado | ||
100mg | Descatalogado |
Información del producto
- Platinum
- dichloro(1,2-cyclohexanediamine-N,N')-
- [SP-4-2-(1R-trans)]-
- Platinum
- dichloro[(1R,2R)-1,2-cyclohexanediamine-kappaN,kappaN']-
- (SP-4-2)- (9CI)
- (SP-4-2)-Dichloro[(1R,2R)-1,2-cyclohexanediamine-kappaN1,kappaN2]platinum
- 1,2-Cyclohexanediamine
- platinum complex
- (1R-trans)-
- Ver más sinónimos
- 1,2-Diamminecyclohexane-dichloroplatinum(II)
- Dichloro((1R,2R)-trans-diaminocyclohexane)platinum(II)
- Dichloro((R,R)-1,2-diaminocyclohexane)platinum
- Dichloro(1R,2R-1,2-diaminocyclohexane)platinum
- Dichloro(1R,2R-cyclohexanediammine)platinum(II)
- Dichloro(trans-R,R-1,2-diaminocyclohexane)platinum
- Dichloro(trans-l-1,2-cyclohexanediamine)platinum(II)
- Dichloro[(1R,2R)-1,2-cyclohexanediamine]platinum
- Dichloro[(R,R)-1,2-cyclohexanediamine]platinum
- Dichloro[trans-(-)-1,2-cyclohexanediamine]platinum(II)
- NSC 265460
- cis-Dichlorobis((1R,2R)-cyclohexanediamine)platinum
- [SP-4-2-(1R-trans)]-(1,2-Cyclohexanediamine-N,N') Dichloridoplatinum(II),Platinum
- dichloro[(1R,2R)-1,2-cyclohexanediamine-?N1,?N2]-
- (SP-4-2)-
- Platinum
- dichloro[(1R,2R)-1,2-cyclohexanediamine-?N,?N']-
- (SP-4-2)- (9CI)
- (SP-4-2)-Dichloro[(1R,2R)-1,2-cyclohexanediamine-?N1,?N2]platinum
- Platinum
- dichloro(1,2-cyclohexanediamine-?N,?N')-
- [SP-4-2-[1R-(trans)]]-
- Platinum
- dichloro[(1R,2R)-1,2-cyclohexanediamine-kappaN1,kappaN2]-
- (SP-4-2)-,
Applications [SP-4-2-(1R-trans)]-(1,2-Cyclohexanediamine-N,N’) dichloridoplatinum(II) is an impurity of Oxiplatin (O845075), third generation platinum complex. An antitumor agent with activity against colorectal cancer. Cytotoxicity follows the formation of adducts with DNA. Antineoplastic.
References Kidani, Y. et al.: Biomed. Pharmacther., 43, 261 (1989); Noji, M. et al.: J. Med. Chem., 24, 508 (1981); Kidani, Y., et al.: J. Med. Chem., 21, 1315 (1978), Kizu, R., et al.: Cancer Chemother. Pharmacol., 31, 475 (1993), Levi, F., et al.: Eur. J. Cancer, 29A, 1280 (1993), Simpson, D., et al.: Drugs, 63, 2127 (2003),